Abstract
Introduction The Coronavirus (COVID-19) Pandemic has caused significant global mortality and impacted lives around the world. Virus Watch aims to provide evidence on which public health approaches are most likely to be effective in reducing transmission and impact of the virus, and will investigate community incidence, symptom profiles, and transmission of COVID-19 in relation to population movement and behaviours.
Methods and analysis Virus Watch is a household community cohort study of acute respiratory infections in England & Wales and will run from June 2020 to August 2021. The study aims to recruit 50,000 people, including 12,500 from minority ethnic backgrounds, for an online survey cohort and monthly antibody testing using home finger prick kits. Nested within this larger study will be a sub-cohort of 10,000 individuals, including 3,000 people from minority ethnic backgrounds. This cohort of 10,000 people will have full blood serology taken between October 2020 and January 2021 and repeat serology between May 2021 and August 2021. Participants will also post self-administered nasal swabs for PCR assays of SARS-CoV-2 and will follow one of three different PCR testing schedules based upon symptoms.
Ethics and dissemination This study has been approved by the Hampstead NHS Health Research Authority Ethics Committee. Ethics approval number – 20/HRA/2320. We are monitoring participant queries and using these to refine methodology where necessary, and are providing summaries and policy briefings of our preliminary findings to inform public health action by working through our partnerships with our study advisory group, Public Health England, NHS and Government Scientific Advisory panels.
Strengths and limitations of this study
Virus Watch is a large national household community cohort study of the occurrence and risk factors for COVID-19 infection that aims to recruit 50,000 people, including 12,500 from minority ethnic backgrounds.
Virus Watch is designed to estimate incidence of PCR confirmed COVID-19 in those with respiratory and non-respiratory presentations and the incidence of hospitalisation among PCR confirmed COVID-19 cases.
Virus Watch will measure effectiveness and impact of recommended COVID-19 control measures including testing, isolation, social distancing, respiratory and hand hygiene measures on risk of respiratory infection.
Only households with a lead householder able to speak English were able to take part in the study up until March 2021.
Only households of up to six people were eligible for inclusion and they were also required to have access to an internet connection. These restrictions will limit the generalisability to large or multigenerational households, and those without access to the internet.
Competing Interest Statement
ACH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. AMJ was a Governor of Wellcome Trust from 2011-18 and is Chair of the Committee for Strategic Coordination for Health of the Public Research.
Funding Statement
The research costs for the study have been supported by the MRC Grant Ref: MC_PC 19070 awarded to UCL on 30 March 2020 and MRC Grant Ref: MR/V028375/1 awarded on 17 August 2020. The study also received $15,000 of advertising credit to support a pilot social media recruitment campaign on 18th August 2020.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the Hampstead NHS Health Research Authority Ethics Committee. Ethics approval number - 20/HRA/2320.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Emails: Andrew Hayward a.hayward{at}ucl.ac.uk, Ellen Fragaszy ellen.fragaszy{at}ucl.ac.uk, Jana Kovar j.kovar{at}ucl.ac.uk, Vincent Nguyen vincent.nguyen.11{at}ucl.ac.uk, Sarah Beale sarah.beale.19{at}ucl.ac.uk, Thomas Byrne t.byrne{at}ucl.ac.uk, Anna Aryee a.aryee{at}ucl.ac.uk, Pia Hardelid p.hardelid{at}ucl.ac.uk, Linda Wijlaars linda.wijlaars{at}ucl.ac.uk, Wing Lam Erica Fong erica.fong.16{at}ucl.ac.uk, Cyril Geismar cyril.geismar.16{at}ucl.ac.uk, Parth Patel parth.patel{at}ucl.ac.uk, Madhumita Shrotri madhumita.shrotri.09{at}ucl.ac.uk, Annalan M D Navaratnam a.navaratnam{at}ucl.ac.uk, Eleni Nastouli e.nastouli{at}ucl.ac.uk, Moira Spyer moira.spyer{at}ucl.ac.uk, Ben Killingley ben.killingley{at}nhs.net, Ingemar Cox i.cox{at}ucl.ac.uk, Vasileios Lampos v.lampos{at}ucl.ac.uk, Rachel A McKendry r.a.mckendry{at}ucl.ac.uk Tao Cheng tao.cheng{at}ucl.ac.uk, Anne M Johnson anne.johnson{at}ucl.ac.uk, Susan Michie s.michie{at}ucl.ac.uk, Jo Gibbs jo.gibbs{at}ucl.ac.uk, Richard Gilson r.gilson{at}ucl.ac.uk, Alison Rodger alison.rodger{at}ucl.ac.uk, Robert W Aldridge r.aldridge{at}ucl.ac.uk
Updated methods and analysis plan.
Data Availability
We aim to share aggregate data from this project on our website and via a 'Findings so far' section on our website (https://ucl-virus-watch.net). We will also be sharing individual record level data with personal identifiers removed on a research data sharing service such as the Office of National Statistics Secure Research Service. In sharing the data we will work within the principles set out in the UKRI Guidance on best practice in the management of research data. Access to use of the data whilst research is being conducted will be managed by the Chief Investigators (ACH and RWA) in accordance with the principles set out in the UKRI guidance on best practice in the management of research data. It is the intention that the data arising from this research will initially be collected, cleaned and validated by the UCL research team and once this has been completed will be shared for wider use. We aim to make subsets of the data more rapidly available both on our study website and via the public facing dashboard during the ongoing phase of data collection. In line with Principle 5 of the UKRI guidance on best practice in the management of research data, we plan to release data in batches as they become available or as updated results are published. Individual record data linked using NHS Digital will not be shared, only aggregated results. HES and mortality data may be obtained from a third party and are not publicly available. These data are owned by a third party and can be accessed by researchers applying to the Health and Social Care Information Centre for England. We will put analysis code on publicly available repositories to enable their reuse.
